World Medical Association, 2008. Declaration of Helsinki. Available at: http://www.wma.net/e/policy/b3.htm. Accessed March 17, 2009.
Sreenivasan G, 2003. Does informed consent to research require comprehension? Lancet 362: 2016–2018.
CIOMS/WHO, 2002. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Available at: http://www.cioms.ch/frame_guidelines_nov_2002.htm. Accessed March 17, 2009.
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996. ICH Harmonized Tripartite Guideline—Guideline for Good Clinical Practice. Geneva: WHO. http://www.ich.org/LOB/media/MEDIA482.pdf. Accessed March 17, 2009.
Thiers FA, Sinskey AJ, Berndt ER, 2008. Trends in the globalization of clinical trials. Nat Rev Drug Discov 7: 13–14.
Annas GJ, Grodin MA, 1998. Human rights and maternal-fetal HIV transmission prevention trials in Africa. Am J Public Health 88: 560–563.
Christakis NA, 1988. The ethical design of an AIDS vaccine trial in Africa. Hastings Cent Rep 18: 31–37.
Flory JH, Wendler D, Emanuel EJ, 2008. Empirical issues in informed consent for research. Emanuel E, Grady C, Crouch R, Lie R, Miller F, Wendler D, eds. The Oxford Textbook of Clinical Research Ethics. New York: Oxford University Press.
Pace C, Grady C, Emanuel E, 2003. What we don't know about informed consent. SciDevNet, August 28, 2003. Available at: http://www.scidev.net/en/opinions/what-we-dont-know-about-informed-consent.html. Accessed July 21, 2010.
Abdool Karim Q, Abdool Karim SS, Coovadia HM, Susser M, 1998. Informed consent for HIV testing in a South African hospital: is it truly informed and truly voluntary? Am J Public Health 88: 637–640.
Lynoe N, Hyder Z, Chowdhury M, Ekstrom L, 2001. Obtaining informed consent in Bangladesh. N Engl J Med 344: 460–461.
Pace C, Talisuna A, Wendler D, Maiso F, Wabwire-Mangen F, Bakyaita N, Okiria E, Garrett-Mayer ES, Emanuel E, Grady C, 2005. Quality of parental consent in a Ugandan malaria study. Am J Public Health 95: 1184–1189.
Ellis RD, Mullen GE, Pierce M, Martin LB, Miura K, Fay MP, Long CA, Shaffer D, Saul A, Miller LH, Durbin AP, 2009. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 27: 4104–4109.
Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, Narum DL, Zhu D, Mullen GE, Mahanty S, Miller LH, Durbin AP, 2010. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS One 5: e8787.
Sagara I, Ellis RD, Dicko A, Niambele MB, Kamate B, Guindo O, Sissoko MS, Fay MP, Guindo MA, Kante O, Saye R, Miura K, Long C, Mullen GE, Pierce M, Martin LB, Rausch K, Dolo A, Diallo DA, Miller LH, Doumbo OK, 2009. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 27: 7292–7298.
Dicko A, Sagara I, Ellis RD, Miura K, Guindo O, Kamate B, Sogoba M, Niambelé MB, Sissoko M, Baby M, Dolo A, Mullen GE, Fay MP, Pierce M, Diallo DA, Saul A, Miller LH, Doambo OK, 2008. Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS ONE 3: e1563.
Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, Sissoko MS, Kone M, Diallo AI, Saye R, Guindo MA, Kante O, Niambele MB, Miura K, Mullen GE, Pierce M, Martin LB, Dolo A, Diallo DA, Doumbo OK, Miller LH, Saul A, 2009. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27: 3090–3098.
United States Code of Federal Regulations, 2005. Title 45 Public Welfare Part 46.
Agresti A, 2002. Categorical Data Analysis. Hoboken, NJ: John Wiley and Sons.
Krosin MT, Klitzman R, Levin B, Cheng J, Ranney ML, 2006. Problems in comprehension of informed consent in rural and peri-urban Mali, West Africa. Clin Trials 3: 306–313.
Minnies D, Hawkridge T, Hanekom W, Ehrlich R, London L, Hussey G, 2008. Evaluation of the quality of informed consent in a vaccine field trial in a developing country setting. BMC Med Ethics 9: 15.
Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC, 2001. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet 358: 1772–1777.
Pace C, Emanuel EJ, Chuenyam T, Duncombe C, Bebchuk JD, Wendler D, Tavel JA, McNay LA, Phanuphak P, Forster HP, Grady C, 2005. The quality of informed consent in a clinical research study in Thailand. IRB 27: 9–17.
Taiwo OO, Kass N, 2009. Post-consent assessment of dental subjects' understanding of informed consent in oral health research in Nigeria. BMC Med Ethics 10: 11.
Kodish E, Eder M, Noll RB, Ruccione K, Lange B, Angiolillo A, Pentz R, Zyzanski S, Siminoff LA, Drotar D, 2004. Communication of randomization in childhood leukemia trials. JAMA 291: 470–475.
Hietanen P, Aro AR, Holli K, Absetz P, 2000. Information and communication in the context of a clinical trial. Eur J Cancer 36: 2096–2104.
van Stuijvenberg M, Suur MH, de Vos S, Tjiang GC, Steyerberg EW, Derksen-Lubsen G, Moll HA, 1998. Informed consent, parental awareness, and reasons for participating in a randomised controlled study. Arch Dis Child 79: 120–125.
Taub HA, 1980. Informed consent, memory and age. Gerontologist 20: 686–690.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1 | 1 | 1 |
Full Text Views | 321 | 137 | 1 |
PDF Downloads | 61 | 44 | 1 |
Initial responses to questionnaires used to assess participants' understanding of informed consent for malaria vaccine trials conducted in the United States and Mali were tallied. Total scores were analyzed by age, sex, literacy (if known), and location. Ninety-two percent (92%) of answers by United States participants and 85% of answers by Malian participants were correct. Questions more likely to be answered incorrectly in Mali related to risk, and to the type of vaccine. For adult participants, independent predictors of higher scores were younger age and female sex in the United States, and male sex in Mali. Scores in the United States were higher than in Mali (P = 0.005). Despite this difference participants at both sites were well informed overall. Although interpretation must be qualified because questionnaires were not intended as research tools and were not standardized among sites, these results do not support concerns about systematic low understanding among research participants in developing versus developed countries.
Financial support: This research was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID).
Authors' addresses: Ruth D. Ellis, Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Heath (MVDB, NIAID/NIH), Rockville, MD, E-mail: ellisru@niaid.nih.gov. Issaka Sagara, Alassane Dicko, Mahamadoun H. Assadou, Mamady Kone, Beh Kamate, Ousmane Guindo, Dapa A. Diallo, and Ogobara K Doumbo, Malaria Research and Training Center (MRTC), Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Bamako, Bamako Mali, E-mails: isagara@icermali.org, adicko@icermali.org, mmaiga@icermali.org, mamady@icermali.org, bkamate@icermali.org, guindoous@icermali.org, dadiallo@icermali.org, and okd@icermali.org. Anna Durbin and Donna Shaffer, Johns Hopkins Center for Immunization Research, Washington, DC, E-mails: adurbin@jhsph.edu and dshaffer@jhsph.edu. Louis Miller, MVDB, NIAID/NIH, Rockville, MD, E-mail: lmiller@niaid.nih.gov. Michael P. Fay, Biostatistics Research Branch, NIAID/NIH, Bethesda, MD, E-mail: mfay@niaid.nih.gov. Ezekiel J. Emmanuel, Clinical Center Department of Bioethics, NIH, Bethesda, MD, E-mail: EEmanuel@cc.nih.gov. Joseph Millum, Clinical Center Department of Bioethics/Fogarty International Center, National Institutes of Health, Bethesda, MD, E-mail: millumj@cc.nih.gov.